Status:
UNKNOWN
Carvedilol Versus Verapamil in Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy
Lead Sponsor:
Medical University of Silesia
Conditions:
Systolic Heart Failure
Myocardial Disease
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
Accumulated clinical and experimental data suggest that dysfunctional coronary microcirculation plays a pivotal role in the progression of heart failure despite an optimal therapy used. Therefore, we ...
Detailed Description
Heart failure, irrespective of its etiology may be viewed as a progressive disorder initiated by a different events and sustained by a multifaceted pathophysiological mechanisms. Regardless of the nat...
Eligibility Criteria
Inclusion
- Chronic heart failure (NYHA II and III; LV ejection fraction, ≤ 35%) secondary to non-ischemic cardiomyopathy. Stable condition at least 6 months before enrollment on conventional therapy (beta-blockers, ACE inhibitors and diuretics).
Exclusion
- improvement in clinical status on conventional therapy in out-patients period preceded hospitalization
- any changes narrowing epicardial coronary arteries in coronary angiography,
- insulin dependent diabetes,
- valvular heart disease (except the relative mitral regurgitation),
- endocrine disease,
- lack of written informed consent,
- significant renal and liver diseases,
- drug or alcohol abuse,
- therapy with steroids or calcium blockers within 3 months before screening
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
End Date :
December 1 2007
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00348530
Start Date
January 1 2006
End Date
December 1 2007
Last Update
October 18 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Silesian Center for Heart Disease, IIIrd Department of Cardiology, Silesian Medical University
Zabrze, Poland, 41-800